Clinical Trial Update: Doxorubicin Hydrochloride Liposome, Bortezomib, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma [Phase 2]

View source ↗

Summary

A Phase 2 study evaluating liposomal doxorubicin, bortezomib, and dexamethasone in newly diagnosed multiple myeloma; the current trial status is unknown.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma
• Plasma Cell Neoplasms

Drugs mentioned

• Bortezomib (bortezomib)
• DEXAMETHASONE (Dexamethasone)
• DOXORUBICIN HYDROCHLORIDE LIPOSOME (DOXORUBICIN HYDROCHLORIDE)

Snippet

Sponsor: Oncotherapeutics | Conditions: Multiple Myeloma and Plasma Cell Neoplasm | Phase 2 | Status: UNKNOWN